

[Acetylsalicylic acid](#)

Statut de médicament essentiel

Section:

[29. Medicines for diseases of joints](#) [29.3. Medicines for juvenile joint diseases](#)

Codes ATC: [N02BA01](#)

EMLc

Indication

Mucocutaneous lymph node syndrome Code ICD11: [4A44.5](#)

Type de médicament

Chemical agent

Type de liste

Liste complémentaire

Additional notes

Acute or chronic use for rheumatic fever, juvenile arthritis , Kawasaki disease

Formulations

Local > Rectal > Suppository: 150 mg ; 300 mg

Oral > Solid > dispersible tablet: 75 mg ; 300 mg ; 500 mg

Oral > Solid > tablet: 75 to 500 mg

Historique des statuts LME

Ajouté pour la première fois en 2007 ([TRS 950](#))

Modifié en 2013 ([TRS 985](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Aussi recommandé pour les enfants

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets.](#)

Wikipédia

[Acetylsalicylic acid](#)

DrugBank

[Acetylsalicylic acid](#)

Résumé des preuves et recommandation du comité d'experts



Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of acetylsalicylic acid: - the lower strength of the range of strengths for acetylsalicylic acid tablets be changed from 100 mg to 75 mg; - removal of the 50 mg strength of suppositories, and addition of 300 mg strength of suppositories; - addition of dispersible tablets (75 g, 300 mg and 500 mg) to facilitate dosing in children unable to swallow solid tablets.